Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics (Nasdaq: VERA) announced that on November 4, 2025 its Compensation Committee granted inducement awards to six new employees under the 2024 Inducement Plan.
The awards include non-qualified stock options to purchase 79,050 shares and restricted stock units covering 39,915 shares. Each option has an exercise price of $24.35, equal to Vera Therapeutics’ closing price on November 4, 2025.
Vesting: options vest over four years with 25% on the first anniversary then monthly over 36 months; RSUs vest over four years with 25% vesting on each anniversary beginning November 20, 2025. Awards are subject to the Inducement Plan and applicable award agreements and were approved as inducements under Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (Nasdaq: VERA) ha annunciato che il 4 novembre 2025 il Compensation Committee ha concesso premi di incentivo a sei nuovi dipendenti nell’ambito del Piano di incentivo 2024.
I premi includono opzioni su azioni non qualificate per l’acquisto di 79.050 azioni e unità azionarie vincolate (RSU) per un totale di 39.915 azioni. Ogni opzione ha un prezzo di esercizio di $24,35, pari al prezzo di chiusura di Vera Therapeutics al 4 novembre 2025.
Vesting: le opzioni maturano in quattro anni con il 25% al primo anniversario e poi mensilmente nei restanti 36 mesi; le RSU maturano in quattro anni con il 25% che matura ad ogni anniversario a partire dal 20 novembre 2025. I premi sono soggetti al Piano di incentivo e agli accordi di premio applicabili e sono stati approvati come incentivi ai sensi della Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (Nasdaq: VERA) anunció que el 4 de noviembre de 2025 su Comité de Compensación otorgó premios de incentivo a seis nuevos empleados bajo el Piano de Incentivos 2024.
Los premios incluyen opciones sobre acciones no calificadas para comprar 79,050 acciones y unidades de acciones restringidas (RSU) que cubren 39,915 acciones. Cada opción tiene un precio de ejercicio de $24.35, equivalente al precio de cierre de Vera Therapeutics el 4 de noviembre de 2025.
Vesting: las opciones se consolidan a lo largo de cuatro años con un 25% en el primer aniversario y luego mensualmente durante 36 meses; las RSU se consolidan a lo largo de cuatro años con un 25% de vesting en cada aniversario a partir del 20 de noviembre de 2025. Los premios están sujetos al Plan de Incentivos y a los acuerdos de premios aplicables y fueron aprobados como incentivos bajo la Regla 5635(c)(4) de Nasdaq Listing.
Vera Therapeutics (Nasdaq: VERA)는 2025년 11월 4일에 보상위원회가 2024년 유인 계획에 따라 여섯 명의 새로운 직원에게 보상금을 부여했다고 발표했습니다.
보상은 79,050주의 비자격 주식매수선택권(NSO)과 39,915주의 제한주식(RSU)을 포함합니다. 각 옵션의 행사가격은 $24.35로, 2025년 11월 4일 Vera Therapeutics의 종가와 동일합니다.
권리의 시가권리: 옵션은 4년에 걸쳐 1년 차에 25%가 vest 되고 이후 36개월 동안 매달 vest; RSU는 4년에 걸쳐 매년 25%가 vesting되며 2025년 11월 20일부터 시작합니다. 보상은 유인 계획 및 해당 보상 계약의 적용을 받으며 Nasdaq Listing Rule 5635(c)(4)에 따라 유인으로 승인되었습니다.
Vera Therapeutics (Nasdaq: VERA) a annoncé que le 4 novembre 2025 son comité de rémunération a accordé des récompenses d’incitation à six nouveaux employés dans le cadre du Piano d’incitation 2024.
Les récompenses comprennent des options d’achat d’actions non qualifiées pour l’achat de 79 050 actions et des unités d’actions restreintes (RSU) couvrant 39 915 actions. Chaque option a un prix d’exercice de $24,35, équivalent au cours de clôture de Vera Therapeutics le 4 novembre 2025.
Vesting : les options se libèrent sur quatre ans avec 25% au premier anniversaire puis mensuellement sur les 36 mois suivants ; les RSU se libèrent sur quatre ans avec 25% qui vestissent à chaque anniversaire à partir du 20 novembre 2025. Les récompenses sont soumises au Plan d’incitation et aux accords de récompense applicables et ont été approuvées comme incitations en vertu de la Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (Nasdaq: VERA) kündigte an, dass am 4. November 2025 sein Vergütungsausschuss induzierte Zuwendungen an sechs neue Mitarbeiter im Rahmen des 2024 Inducement Plans gewährt hat.
Zu den Zuwendungen gehören nicht qualifizierte Aktienoptionen zum Erwerb von 79.050 Aktien und Restricted Stock Units (RSUs) über 39.915 Aktien. Jede Option hat einen Ausübungspreis von $24,35, entsprechend dem Schlusskurs von Vera Therapeutics am 4. November 2025.
Vesting: Optionen vesten über vier Jahre mit 25% am ersten Jahrestag und dann monatlich über 36 Monate; RSUs vesten über vier Jahre mit 25% Vesting an jedem Jahrestag beginnend am 20. November 2025. Die Zuwendungen unterliegen dem Inducement Plan und den anwendbaren Zuwendungsvereinbarungen und wurden als Anreize gemäß der Nasdaq Listing Rule 5635(c)(4) genehmigt.
Vera Therapeutics (Nasdaq: VERA) أعلنت أن لجنة التعويض لديها قد منحت جوائز تحفيز لستة موظفين جدد بموجب خطة التحفيز 2024 في 4 نوفمبر 2025.
تشمل الجوائز خيارات أسهم غير مؤهلة لشراء 79,050 سهماً ووحدات أسهم مقيدة (RSU) تغطي 39,915 سهماً. كل خيار بسعر تنفيذ قدره $24.35، يساوي سعر إغلاق Vera Therapeutics في 4 نوفمبر 2025.
الاستحقاق: تستحق الخيارات خلال أربع سنوات بنسبة 25% في السنة الأولى ثم شهرياً على مدى 36 شهراً؛ تستحق RSUs خلال أربع سنوات بنسبة 25% في كل عيد ميلاد ابتداءً من 20 نوفمبر 2025. تخضع الجوائز لخطة التحفيز ولأحكام جوائز التطبيق المعمول بها وقد تمت الموافقة عليها كحوافز وفقاً لـ قاعدة إدراج Nasdaq 5635(c)(4).
- None.
- None.
BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 79,050 shares of Class A common stock and restricted stock units (RSUs) underlying 39,915 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on November 4, 2025 has an exercise price per share equal to
About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
FAQ
What inducement awards did Vera Therapeutics (VERA) grant on November 4, 2025?
What is the exercise price for the VERA stock options granted November 4, 2025?
How do the VERA option and RSU vesting schedules work for the November 2025 grants?
How many employees received inducement awards from Vera Therapeutics on November 4, 2025?
Under what Nasdaq rule were the VERA inducement awards approved?
